Clinical Trial Update: Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans in Lung Transplant [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing Simulect (basiliximab) plus standard immunosuppression to standard immunosuppression alone for prevention of acute rejection …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency
• Chronic Obstructive Pulmonary Disease
• Emphysema

Drugs mentioned

• Simulect (Basiliximab)

Snippet

Sponsor: University Health Network, Toronto | Conditions: COPD, Emphysema | Phase 3 | Status: COMPLETED